Our Pricing

Wegovy Tablet vs Injection: Which Is Better for Weight Loss in the UK?

Published: 27 August 2026

When considering wegovy tablet vs injection which is better for your weight loss journey, understanding the key differences between these two semaglutide formulations is essential. Both Wegovy oral tablets and Wegovy injections contain the same active ingredient—semaglutide—but differ significantly in administration route, dosing schedules, and patient experience. This comprehensive guide from our UK-registered clinical team examines the evidence to help you make an informed choice.

How Do Wegovy Tablet vs Injection Compare in Effectiveness?

When evaluating wegovy tablet vs injection which is better for weight loss outcomes, clinical trial data provides crucial insights. The STEP trial programme demonstrated that Wegovy injection (semaglutide 2.4mg subcutaneous) achieved average weight loss of 15-17% of initial body weight over 68 weeks in adults with obesity [1]. The oral semaglutide formulation, originally studied at lower doses for type 2 diabetes, has shown comparable efficacy when dosed appropriately for weight management [2].

Both formulations work through the same mechanism—acting as GLP-1 receptor agonists that reduce appetite, slow gastric emptying, and improve glycaemic control. The bioavailability differs: oral semaglutide requires absorption enhancers to overcome the degradation that occurs in the gastrointestinal tract, whilst subcutaneous injection delivers the medication directly into the bloodstream [3]. Clinical studies suggest that when dose-adjusted appropriately, oral and injectable semaglutide can achieve similar therapeutic outcomes, though individual response varies based on adherence, lifestyle factors, and metabolic characteristics.

Clinical Trial Evidence for Both Formulations

The STEP 1 trial established Wegovy injection as a highly effective weight loss intervention, with participants losing an average of 14.9% body weight compared to 2.4% with placebo over 68 weeks [1]. For oral semaglutide, the PIONEER trials initially focused on glycaemic control, but subsequent weight management studies have demonstrated significant weight reduction with higher oral doses. In the OASIS 1 trial, oral semaglutide 50mg once daily produced mean weight loss of approximately 15.1% over 68 weeks in adults with obesity [4]. These findings suggest that both formulations can deliver clinically meaningful weight loss when prescribed and monitored appropriately by UK healthcare professionals.

Wegovy Tablet vs Injection: Which Offers Greater Convenience?

Convenience is a major consideration when deciding wegovy tablet vs injection which is better for your lifestyle. Wegovy tablets are taken orally once daily, typically first thing in the morning on an empty stomach with a small amount of water, followed by a 30-minute wait before eating or drinking [2]. This daily routine may suit individuals who prefer not to use needles or who have needle phobia. However, the strict timing requirements—taking the tablet at least 30 minutes before food—can be challenging for those with variable morning schedules.

Wegovy injections, by contrast, are administered once weekly using a pre-filled, single-use pen device. The subcutaneous injection takes seconds to complete and can be given at any time of day, with or without food, offering greater scheduling flexibility [3]. Many patients find the weekly dosing easier to remember and integrate into their routine compared to daily oral medication. The injection pens are discreet, portable, and designed for self-administration with minimal training required from your prescriber or pharmacist.

Side Effects: Wegovy Tablet vs Injection Which Is Better Tolerated?

Understanding the side effect profiles is essential when comparing wegovy tablet vs injection which is better for tolerability. Both formulations share common GLP-1 receptor agonist side effects, predominantly gastrointestinal in nature. Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort are reported with both routes of administration, typically most pronounced during dose escalation phases [1][3].

Oral semaglutide may be associated with a slightly higher incidence of gastrointestinal side effects due to local effects in the stomach and the absorption enhancer (SNAC) used in the tablet formulation [2]. Injection-site reactions—such as redness, itching, or mild swelling—can occur with Wegovy injections but are generally mild and transient [3]. Clinical experience at Cured Pharmacy shows that side effect severity often diminishes with continued use and gradual dose titration. Your UK prescriber will assess your medical history and tolerance to recommend the most appropriate formulation and starting dose for your individual circumstances.

Managing Side Effects with Either Formulation

Regardless of whether you choose the tablet or injection, effective side effect management improves adherence and treatment success. Starting at the lowest therapeutic dose and following the prescribed escalation schedule minimises gastrointestinal symptoms. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can further reduce nausea and discomfort [3]. If side effects persist or become intolerable, your prescriber may adjust the dose, slow the titration, or consider switching formulations. Both Wegovy tablet and injection require ongoing clinical monitoring to ensure safety and optimise outcomes.

Cost Comparison: Wegovy Tablet vs Injection Which Is Better Value?

Pricing is a practical consideration when determining wegovy tablet vs injection which is better for your budget. At Cured Pharmacy, Wegovy oral tablets start from £124.99, whilst Wegovy injections begin at £124.99, both subject to clinical assessment and prescriber approval. These transparent upfront prices reflect the UK's competitive weight loss medication market, and all treatments are dispensed by our GPhC-registered pharmacy with full clinical oversight.

When evaluating cost-effectiveness, consider not only the upfront price but also the dosing frequency and treatment duration. Wegovy tablets are taken daily, whilst injections are weekly, which may influence the overall monthly expenditure depending on the prescribed dose strength. New patients can Save £20 on their first order using code Weightlossnew, making either formulation more accessible. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), and the clinical team ensure all pricing remains transparent and that patients receive genuine UK-licensed medicines at the lowest guaranteed UK prices.

Patient Preferences: Wegovy Tablet vs Injection Which Is Better for You?

Individual preferences play a significant role in determining wegovy tablet vs injection which is better for long-term adherence. Patients with needle aversion or anxiety around injections may find the oral tablet formulation less intimidating and easier to incorporate into daily life. Conversely, those who struggle with daily medication routines or have difficulty remembering to take pills may prefer the simplicity and reduced frequency of a once-weekly injection [4].

Lifestyle factors also matter: if you travel frequently or have an irregular schedule, the flexibility of weekly injections that can be taken at any time of day may be advantageous. On the other hand, if you prefer not to carry injection devices or are concerned about proper storage and disposal of needles, the oral tablet offers a more conventional medication experience. Discussing these preferences openly with your UK prescriber during the online consultation ensures the chosen formulation aligns with your daily routine, treatment goals, and personal comfort.

Switching Between Formulations

In some cases, patients may wish to switch from Wegovy injection to tablet or vice versa due to tolerability, convenience, or personal preference. Transitioning between formulations should always be done under the guidance of a UK-registered prescriber, as dose equivalence and titration schedules differ between oral and injectable semaglutide [2][3]. Your clinical team at Cured Pharmacy can facilitate this transition safely, ensuring continuity of care and ongoing monitoring throughout your weight loss journey.

Making the Choice: Wegovy Tablet vs Injection Which Is Better Overall?

Ultimately, deciding wegovy tablet vs injection which is better depends on your individual medical profile, lifestyle, and treatment preferences. Both formulations deliver the proven benefits of semaglutide for weight management, supported by robust clinical trial evidence and regulatory approval from the MHRA. The injection offers weekly convenience and flexible timing, whilst the tablet provides a needle-free, oral alternative with daily dosing.

At Cured Pharmacy, our UK-registered clinical team conducts a thorough online assessment to evaluate your suitability for either formulation. This free consultation, completed in under three minutes, considers your medical history, current medications, weight loss goals, and personal preferences. Based on this assessment, a UK prescriber will recommend the most appropriate option and prescribe accordingly. Both Wegovy tablet and injection are dispensed with full clinical support, discreet packaging, and next-day delivery across the UK, ensuring you receive safe, effective, and convenient weight loss treatment tailored to your needs.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 27 August 2026]
2. Pieber, T. R., Bode, B., Mertens, A., et al. (2019). Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology, 7(7), 528-539. [accessed 27 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 27 August 2026]
4. Knop, F. K., Aroda, V. R., do Vale, R. D., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705-719. [accessed 27 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 27 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 27 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 27 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.